Sangamo reports positive Fabry gene therapy data, Q2 net loss narrows to $20M

SANGAMO THERAPEUTICS, INC

2025-Q2 EPS reported -$0.21 revenue$24,743,000

Positive topline from registrational STAAR study: mean annualized eGFR slope +1.965 at 52 weeks across all 32 dosed Fabry patients; FDA agrees as primary basis for accelerated approval.
BLA submission for isaralgagene civaparvovec expected as early as Q1 2026; business development for Fabry commercialization ongoing.
First clinical site initiated for Phase 1/2 STAND study in chronic neuropathic pain; first patient dosing expected fall 2025, preliminary efficacy data Q4 2026.
Q2 2025 revenue $18.3M (vs $0.3M YoY) driven by Lilly license payment; net loss $20.0M ($0.08 EPS) vs $36.1M ($0.18 EPS) prior year.
Cash $38.3M as of June 30; raised ~$21M net from equity offering; expects funding into Q4 2025; reaffirms 2025 opex guidance $135-155M GAAP.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.